AlconXSWX:ALCE +3.65%53 Graham Number is CHF19.14 as of Mar. 2026, which is 100% below its 10-year median of 5.98. GuruFocus rates XSWX:ALCE with a GF Score™ of 53/100 and a GF Value™ of CHF73.46 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 400 Medical Devices & Instruments companies, Alcon ranks worse than 72.75% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-06-25), the stock price of Alcon is CHF55.60. Alcon's graham number for the quarter that ended in Mar. 2026 was CHF19.14. Therefore, Alcon's Price to Graham Number ratio for today is 2.90.
The historical rank and industry rank for Alcon's Graham Number or its related term are showing as below:
XSWX:ALCE'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.4 Med: 5.98 Max: 18.24
Current: 2.88
During the past 10 years, the highest Price to Graham Number ratio of Alcon was 18.24. The lowest was 1.40. And the median was 5.98.
XSWX:ALCE's Price-to-Graham-Number is ranked worse than 72.75% of 400
companies
in the Medical Devices & Instruments industry
Industry Median: 1.785
vs XSWX:ALCE: 2.88
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Alcon (XSWX:ALCE) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Alcon's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
55.60
/
19.14
=
2.90
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Alcon Graham Number Related Terms
Alcon Graham Number Historical Data
* Premium members only.
The historical data trend for Alcon's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ALCE vs ISRG, BDX, MDLN: Graham Number Comparison
For the Medical Instruments & Supplies subindustry, Alcon's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcon Price-to-Graham-Number vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alcon's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Alcon's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcon (XSWX:ALCE) has a Graham Number of CHF19.14 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Alcon and its competitors. This is 220% above median its historical median of 5.98. Over the past decade, Alcon's Graham Number has ranged from 1.40 to 18.24. According to the industry distribution chart, Alcon ranks #291 out of 400 companies in the Medical Devices & Instruments industry, placing it in the top 72.7%.
Is Alcon's Graham Number too high?
Alcon's current Graham Number of CHF19.14 is 220% above median its 10-year median of 5.98. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 18.24. Based on the distribution chart, Alcon ranks #291 out of 400 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Alcon has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's Graham Number compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #291 out of 400 companies for Graham Number. This places Alcon in the lower half of its industry. The industry median Graham Number is 1.79. Historically, Alcon's own Graham Number has ranged from 1.40 to 18.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Medical Devices & Instruments company?
The median Graham Number among Medical Devices & Instruments companies is 1.79, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Alcon and its competitors. For the Medical Devices & Instruments industry, the median Graham Number is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current Graham Number is CHF19.14, which is 220% above median its own 10-year median of 5.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALCE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF73.46, compared to a current price of CHF55.60 — trading 24.3% below its estimated fair value. The current Graham Number is CHF19.14, which is 220% above median its 10-year median of 5.98. Alcon's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Alcon (XSWX:ALCE), the current Graham Number is CHF19.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcon (XSWX:ALCE) Overvalued in 2026?
Based on GuruFocus' analysis, Alcon stock appears to be undervalued.
The current stock price of CHF55.60 is trading 24.3% below its estimated GF Value™ of CHF73.46.
GuruFocus considers Alcon to be Modestly Undervalued.
Key valuation signals for XSWX:ALCE:
Graham Number: CHF19.14 (220% above median its 10-year median of 5.98)
GF Value™: CHF73.46 vs. price of CHF55.60 (24.3% below fair value)
No single metric tells the full story. See the XSWX:ALCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
53GF Score
Get the complete analysis for XSWX:ALCE
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ALCE has been successfully added to your 
